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Objectives
Kaposi’s sarcoma (KS), invasive cervical carcinoma (ICC) and non-Hodgkin lymphoma (NHL)
have been listed as AIDS-defining cancers (ADCs) by the Centers for Disease Control and
Prevention since 1993. Despite this, HIV screening is not universally mentioned in ADC
treatment guidelines. We examined screening practices at a tertiary centre serving a population
where HIV seroprevalence is 0.4%.
Methods
Patients with KS, ICC, NHL and Hodgkin lymphoma (HL), treated at Lausanne University Hospital
between January 2002 and July 2012, were studied retrospectively. HIV testing was considered
part of the oncology work-up if performed between 90 days before and 90 days after the cancer
diagnosis date.
Results
A total of 880 patients were examined: 10 with KS, 58 with ICC, 672 with NHL and 140 with
HL. HIV testing rates were 100, 11, 60 and 59%, and HIV seroprevalence was 60, 1.7, 3.4 and
5%, respectively. Thirty-seven patients (4.2%) were HIV-positive, of whom eight (22%) were
diagnosed at oncology work-up. All newly diagnosed patients had CD4 counts < 200 cells/μL
and six (75%) had presented to a physician 12–236 weeks previously with conditions warranting
HIV testing.
Conclusions
In our institution, only patients with KS were universally screened. Screening rates for other
cancers ranged from 11 to 60%. HIV seroprevalence was at least fourfold higher than the
population average. As HIV-positive status impacts on cancer patient medical management, HIV
screening should be included in oncology guidelines. Further, we recommend that opt-out
screening should be adopted in all patients with ADCs and HL.
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Introduction
Although Kaposi’s sarcoma (KS), invasive cervical cancer
(ICC) and non-Hodgkin lymphoma (NHL) have been listed
as AIDS-defining cancers (ADCs) since 1993 [1], HIV
testing is not universally proposed in ADC treatment
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guidelines. Testing is implicit for KS, as part of staging,
recommended for NHL [2], but not mentioned for ICC
[3,4]. Testing is also recommended in Hodgkin lymphoma
(HL) [5], given its high incidence in HIV-positive patients
[6]. Testing in ADC patients is beneficial and logical:
in lymphoma, outcome is optimized when co-existing
HIV infection is also treated [7,8]; in ICC, the leading
cause, human papillomavirus, and HIV share transmission
routes.
In 2006, the Centers for Disease Control and Prevention
recommended nontargeted ‘opt-out’ HIV testing in all set-
tings where local undiagnosed HIV seroprevalence is
≥ 0.1% [9]. In Europe, most national testing recommenda-
tions are ‘opt-in’: the 2008 British HIV Association guide-
lines recommend diagnostic testing and targeted screening
[10]; in Switzerland, where estimated HIV seroprevalence is
0.4% [11], physician-initiated counselling and testing
(PICT) has been recommended since 2007 [12]. The Swiss
PICT recommendations list ADCs among testing indica-
tions. However, the degree of translation of these recom-
mendations into clinical practice is unclear: there was no
change in testing rates in our 1300-bed hospital when the
recommendations were updated, and rates among oncol-
ogy patients remained very low (< 5%) [13]. The primary
objective of this study was therefore to determine HIV
testing rates among patients treated for ADCs and HL at
our centre.
Methods
This study was approved by the ethics committee on
human scientific research of the canton of Vaud, Switzer-
land. Patients aged ≥ 18 years treated for KS, ICC, NHL and
HL between 1 January 2002 and 31 July 2012 were studied
retrospectively.
HIV testing was considered as related to oncology
work-up if performed within 90 days before and 90 days
after the cancer diagnosis date, based on local clinical
experience (SP and CA). Patients were classified as HIV
‘tested’ upon identification of [1] documented testing in the
hospital database or [2] a reference to testing performed
elsewhere. Testing date, result and, where positive, baseline
CD4 count were recorded. Patients were further cross-
referenced against the Lausanne arm of the Swiss HIV
Cohort Study (SHCS), with an ongoing, continuous enrol-
ment [14], to identify HIV-positive diagnoses made after
the oncology event. Patients not ‘tested’ were classified as
‘not tested’, or ‘missing data’ when records were insuffi-
ciently comprehensive to determine testing status. Patient
demographic data were recorded.
HIV testing rate was calculated using a modified equa-
tion described previously [13]:
number of patients HIV tested total number of patients
nu
([
− mber of patients known to be HIV positive)] ×100.
HIV seroprevalence was also calculated:
number of patients identified as HIV positive at
oncology
([
 work-up number of patients known to
be HIV positive total
+
)  number of patients] ×100.
Data analysis was performed after patient anonymization.
Given the different demographic profiles of the ADCs exam-
ined, each ADC was analysed separately. Means were com-
pared using Student’s t-test and proportions compared using
the χ2 test. All analyses were performed using Microsoft
Excel 2008 (Microsoft Corporation, Redmond, WA).
Results
Of 880 patients attending our centre during the study
period, 10 had KS, 58 ICC, 672 NHL and 140 HL. A total of
610 patients (of 880; 69%) were ‘tested’, most (79%) within
90 days before and 90 days after their cancer diagnosis
date. Patients tested > 90 days after their cancer diagnosis
were mostly NHL patients (78%).
For HIV testing rate and seroprevalence calculations,
‘missing data’ patients [22 of 672 patients (3.3%) with NHL
and six of 140 patients (4.3%) with HL] were grouped with
‘not tested’ patients. Calculations pertain to the whole
study period, as rates remained static between calendar
years (data not shown). Testing rates and seroprevalence
figures are shown in Table 1. Mean age was lower in
‘tested’ compared with ‘not tested’ NHL patients (55 vs 62
years, respectively; P < 0.0001), and testing rate was higher
among younger (≤ 55 years old) than older (> 55 years old)
NHL patients (68% vs 54%, respectively; P = 0.01). No age
difference was observed in other cancer categories. Testing
rates did not differ with sex, marital status or origin
(Table 1).
Of 37 HIV-positive patients, eight (22%) were diagnosed
at oncology work-up, all with CD4 counts < 200 cells/μL.
Seven (88%) had consulted a doctor a median of 76 weeks
(range 8-236 weeks) prior to their ADC presentation, and
six (75%) had presented with criteria for HIV testing
according to national recommendations (Table S1). No
patient ‘not tested’ at cancer diagnosis was subsequently
identified as HIV positive.
Discussion
In this 10-year retrospective analysis of oncology patients,
we observe HIV testing rates of 59-60% in lymphoma
patients, 11% in ICC patients, and 100% in KS patients.
Among NHL patients, we observe a significant inverse
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relationship between testing rate and patient age. Eight
new HIV-positive diagnoses were made at oncology work-
up. Assuming all untested patients were HIV negative, HIV
seroprevalence among ICC, NHL and HL patients was 1.7,
3.4 and 5%, respectively; seroprevalence among KS
patients was 60%.
The low testing rate in ICC patients is surprising, given
that ICC is an ADC. The authors of the HIV Indicator
Diseases across Europe Study (HIDES 1) recently concluded
that HIV screening in patients with cervical cancer of any
stage is cost effective and should be recommended [15].
However, neither European nor American ICC guidelines
currently mention testing [3,4].
The testing rate in lymphoma patients is suboptimal,
when treatment guidelines recommend testing [2,5]. The
inverse relationship between testing rates and patient age
in NHL patients goes against the emerging trend of increas-
ing numbers of adults aged > 50 years accessing HIV care
[16]. Older individuals often present at late stages of infec-
tion, with increased associated morbidity, mortality and
health care costs [16,17]. Undiagnosed, and therefore
untreated, infection also favours onward transmission.
Finally, it is concerning that the eight newly diagnosed
patients had to develop cancer to be diagnosed with HIV
infection, despite the fact that six had previously consulted
for reasons that should have prompted earlier HIV testing.
This study has limitations. We examined testing
performed rather than testing offered, so may have
misclassified patients declining testing as ‘not tested’.
Against this, we have observed that most patients are
agreeable to routine testing pre-surgery [18]. Among lym-
phoma patients, we did not examine whether testing was
prompted by diagnosis or anticipated treatment as we
examined whether HIV testing was performed, not why. If
testing is performed in anticipation of risk-related treatment
options, this could explain the low testing rate in ICC, where
chemotherapy schedules have less impact on host immunity.
In conclusion, we observed suboptimal HIV testing rates
among patients with ICC and lymphoma, and lower testing
rates with increasing age among NHL patients. HIV
seroprevalence was at least fourfold higher than the popula-
tion average. To our knowledge, this is the first study exam-
ining a decade of HIV testing rates for all three ADCs. Given
the impact of HIV-positive status on the medical management
of cancer patients, we propose that treatment guidelines
should mention HIV testing for ICC patients, and that opt-out
testing should be adopted in all patients with ADCs and HL.
Exploring barriers to testing oncology patients, beyond the
lack of guidelines, is a crucial parallel measure.
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Table 1 Demographic characteristics of study patients, HIV testing rates and HIV seroprevalence, grouped by cancer diagnosis
ICC
Pa
NHL
Pa
HL
PaTested
Not
tested Tested
Not
tested Tested
Not
tested
Number of patients [n (%)] 6 (11) 51 (89) 392 (60) 261 (40) 79 (59) 54 (41)
Number of men [n (%)] NA NA – 230 (59) 161 (62) > 0.5 44 (56) 32 (59) > 0.5
Age (years) [median (IQR)] 49 (36–58) 54 (44–65) > 0.5 57 (45–66) 62 (52–74) 0.01 32 (27–51) 36 (27–59) 0.6
Married/widowed [n (%)] 2 (33) 26 (51) > 0.5 276 (70) 187 (72) > 0.5 40 (51) 29 (54) > 0.5
Origin [n (%)]
Switzerland and North/West Europe 4 (67) 37 (73) > 0.5 300 (77) 219 (84) 0.27 53 (67) 38 (70) > 0.5
Other* 2 (33) 14 (27) 92 (23) 42 (16) 26 (33) 16 (30)
HIV-positive patients [total (n diagnosed at
oncology work-up)]
1 (0) 23 (4) 7 (0)
HIV seroprevalence, based on all patients as
denominator [% (95% CI)]†
1.7 (NA; < 5 HIV-positive patients†) 3.4 (2.0–4.8) 5 (1.4–8.6)
HIV seroprevalence, based on ‘tested’ patients
only as denominator [% (95% CI)]†
16 (NA; < 5 HIV-positive patients†) 5.9 (3.6–8.2) 8.9 (5.7–12.1)
ICC, invasive cervical carcinoma; IQR, interquartile range; NHL, non-Hodgkin lymphoma; HL, Hodgkin lymphoma; IQR, interquartile range; NA, not applicable.
aP-values are specified where P < 0.5 (χ2 test); those for patient origin are calculated for patients from Switzerland and North/West Europe against those
of all other origin. *Asia, Africa, South/East Europe, Middle East and America. †For cancer groups with testing rates < 100%, seroprevalence was calculated
taking tested as well as all patients as the denominator, as assuming that all ‘not tested’ patients were HIV negative could underestimate true HIV
seroprevalence. The 95% confidence interval (CI) is calculated for cancer groups with > 5 HIV-positive patients. The 10 Kaposi’s sarcoma patients are not
included in this table as HIV testing rate was 100%. Among these patients, nine (90%) were men, median age was 59 years (IQR 49–62 years), and seven
(70%) were from Switzerland or North/West Europe; seroprevalence was six of 10 (60%), with four of the six patients being newly diagnosed at oncology
work-up.
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Supporting information
Additional Supporting Information may be found in the
online version of this article at the publisher’s web-site:
Table S1 Previous consultation histories of the eight
patients newly diagnosed as HIV-positive as a result of
their oncology work-ups. Abbreviations: KS, Kaposi’s
sarcoma; NHL, non-Hodgkin lymphoma.
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